TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TELA Bio (NASDAQ: TELA) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference.

Rhea-AI Summary

TELA Bio (NASDAQ: TELA) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference. Company management is scheduled to present at 8:30 a.m. ET on August 12, 2026. A live and archived webcast of the presentation will be available at ir.telabio.com.

Argus Jul 30 session 3 alerts

+4.77% close to close 0.3x rel. volume Open Argus

Details

News Market Reaction – TELA

$32.32M Market Cap

On Jul 30, the first trading day after this news, TELA closed 4.77% above the previous close. Our momentum scanner recorded 3 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 30 session.

Market Context

TELA's prior earnings release (news_id 1056158) was followed by a -5.88% 24-hour reaction, adding hi...

Analysis

TELA's prior earnings release (news_id 1056158) was followed by a -5.88% 24-hour reaction, adding historical comparison to this conference scheduling notice. The active S-3 resale registration and low short positioning provide platform-record risk context; subsequent company disclosures remain the key reference.

Key Figures

Conference edition: 46th annual Presentation time: 8:30 am ET Presentation date: August 12th, 2026

Conference edition

46th annual

Canaccord Genuity Growth Conference

Presentation time

8:30 am ET

August 12, 2026 conference presentation

Presentation date

August 12th, 2026

Canaccord Genuity Growth Conference

Historical Context

5 past events · Latest: Jul 20

5 events

1. Jul 20

   Earnings date notice

   24h Move

   +0.0%

   Announced August 10 release date and conference call for second-quarter results

2. May 12

   Earnings report

   24h Move

   -5.9%

   Reported revenue growth, European expansion, cash balance, and 2026 guidance

3. May 07

   Equity inducement grants

   24h Move

   -7.3%

   Granted restricted stock units covering 89,250 shares to twelve newly hired employees

4. Apr 30

   Board refresh announcement

   24h Move

   +13.1%

   Announced four director departures, four incoming leaders, and preliminary revenue above guidance

5. Apr 21

   Earnings date notice

   24h Move

   +0.7%

   Scheduled May 12 financial-results release and management conference call

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

soft-tissue reconstruction

1 terms

soft-tissue reconstruction medical

"focused on providing innovative soft-tissue reconstruction solutions"

Surgical methods to repair, replace or rebuild damaged soft tissues such as skin, muscle, fat and tendons, often using grafts, tissue flaps, scaffolds or implants. Investors care because these procedures drive demand for medical devices, biologic products and hospital services, affect treatment costs and reimbursement, and are influenced by clinical outcomes and regulatory approvals—similar to how repairing a ripped fabric requires different tools and materials, altering market needs and revenue opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46^th Annual Growth Conference.

TELA’s management is scheduled to present at the Canaccord Genuity 46^th Annual Growth Conference at 8:30 am ET on August 12^th, 2026. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Investor Contact
Louisa Smith
ir@telabio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will TELA Bio (NASDAQ: TELA) present at the Canaccord Genuity 46th Annual Growth Conference in 2026?

TELA Bio is scheduled to present at 8:30 a.m. ET on August 12, 2026. According to TELA Bio, this presentation is part of the Canaccord Genuity 46th Annual Growth Conference and will be accessible via webcast.

How can investors access TELA Bio's webcast from the Canaccord Genuity 46th Annual Growth Conference?

Investors can access TELA Bio’s live and archived webcast at ir.telabio.com. According to TELA Bio, the conference presentation will be streamed there, allowing both real-time viewing and later replay.

What event is TELA Bio participating in on August 12, 2026?

TELA Bio will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. According to TELA Bio, company management is scheduled to deliver a presentation at 8:30 a.m. ET with online webcast access.

Is a replay of TELA Bio’s Canaccord Genuity 46th Annual Growth Conference presentation available for shareholders?

Yes, an archived webcast of TELA Bio’s presentation will be available. According to TELA Bio, both the live and archived versions can be accessed through the company’s investor relations website at ir.telabio.com.

Where is information about TELA Bio’s participation in the Canaccord Genuity 46th Annual Growth Conference hosted?

Information and webcast access for TELA Bio’s conference presentation are hosted at ir.telabio.com. According to TELA Bio, this investor relations site will stream the live event and provide subsequent on-demand access.